

Minnesota Board of Pharmacy

Retreat – August 17, 2017

At approximately 9:00 a.m., on August 17, 2017, the Minnesota Board of Pharmacy met at Henson and Efron, 220 South 6th Street, Suite 1800, Minneapolis, Minnesota for the purpose of conducting a retreat. The purpose of the retreat was for the Board's legal counsel and staff to provide background information to the Board Members on a variety of issues. No votes were taken on any subject. Members of the Board that attended were Mr. Stuart Williams, Mr. Rabih Nahas, Mr. James Bialke, Dr. Andrew Behm, Dr. Kurt Henn, Ms. Samantha Jaworski, Ms. Laura Schwartzwald, Dr. Mary Phipps, and Dr. Joseph Stanek. Also in attendance were the Board's Executive Director, Dr. Cody Wiberg; Deputy Director, Dr. Beth Ferguson; Legal Counsel, Mr. Hans Anderson; and Board staff members, Ms. Barb Carter, Ms. Michele Mattila, Ms. Ame Carlson, Dr. Sarah Favour, Mr. Steve Huff, and Mr. Tim Litsey.

President Stuart Williams called the meeting to order.

Mr. Anderson and Dr. Wiberg provided the Board with information concerning various statutes, rules and procedures that are pertinent to the Board's operation. Mr. Anderson addressed disciplinary case procedures, Minnesota's open meeting law, and recusals, conflicts of interests, and gifts. Dr. Wiberg addressed Chapter 214 provisions relevant to health licensing boards, variances and the Minnesota Data Practices Act. They both answered questions that Board Members and staff had about these issues.

Mr. Josh Bolin, of the National Association of Boards of Pharmacy (NABP), next gave an update on various issues affecting boards of pharmacy across the country.

Dr. Wiberg then briefly provided an update concerning the budget-making process and the current status of the Board's budget. He also briefly mentioned provided an update on recruitment efforts for three staff members who had either resigned or announced retirements.

The Board then recessed for lunch.

After reconvening, Dr. Wiberg and Dr. Ferguson provided the Board Members with background information concerning several policy areas, including: telepharmacy, automated drug distribution systems, and compounding. They both answered questions that Board Members and staff had about these issues.

Dr. Wiberg then gave a brief presentation concerning some of the issues that were in the Board's 2017 policy legislation and informed the Board that he would provide additional information during upcoming Board meetings. He also mentioned that staff had begun work on possible rule changes and would provide the Board Members with more detailed information and recommendations at future Board meetings.

In the interest of time, the decision was made to have Ms. Carter give her Prescription Monitoring Program presentation at the Board's next regularly scheduled business meeting.

Mr. Williams adjourned the meeting at approximately 4:30PM.

PRESIDENT

EXECUTIVE DIRECTOR